<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217009</url>
  </required_header>
  <id_info>
    <org_study_id>2435-04</org_study_id>
    <nct_id>NCT00217009</nct_id>
  </id_info>
  <brief_title>Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.</brief_title>
  <official_title>A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      Hand and foot skin diseases, such as dermatitis and psoriasis, that do not respond to topical
      creams can be treated with ultraviolet light therapy. Topical psoralen plus ultraviolet A
      (PUVA) is commonly used to treat these conditions, but requires additional time for the hands
      and feet to soak in psoralens before the light treatment. Newer narrowband ultraviolet B
      (NBUVB) units have become available which allow for light treatment without soaking first.
      The purpose of this study is to determine if NBUVB is as effective as PUVA for hand and foot
      skin diseases.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unfortunately we had unforeseen difficulty recruiting to this study. Therefore we have decided
    to halt the study and not publish the results.
  </why_stopped>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatments required to reach clearance</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in symptom score (erythema, scaling/hyperkeratosis, papular/vesicular eruption, and fissures)</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global score</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reaching clearance</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in remission</measure>
    <time_frame>Baseline to 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Dermatitis</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Narrowband Ultraviolet B (TL-01UVB) Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatments - 3x weekly for 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Psoralen plus ultraviolet A (PUVA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatments - 3x weekly for 15 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Narrowband Ultraviolet B (TL-01UVB) Therapy</intervention_name>
    <arm_group_label>Narrowband Ultraviolet B (TL-01UVB) Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Topical Psoralen plus ultraviolet A (PUVA)</intervention_name>
    <arm_group_label>Topical Psoralen plus ultraviolet A (PUVA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Bilateral hand or foot skin disease (dermatitis, psoriasis, etc.) with symmetric
        distribution and severity.

        Exclusion Criteria:

        Age &lt;18 years Pregnancy Liver disease Kidney disease History of skin cancer Phototherapy or
        systemic therapy for the skin condition in the preceding 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <name_title>Mark D Davis, M.D</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amotosalen</mesh_term>
    <mesh_term>Furocoumarins</mesh_term>
    <mesh_term>Ficusin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

